Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Plus Chemotherapy With or Without Additional Treatments in Perioperative Resectable NSCLC
NCT06465329Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2029
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of dalmitamig, REGN10597 in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Nov 2024; status: active, not recruiting.
02
Drugs
dalmitamigREGN10597
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06465329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465329.